Maze Therapeutics (MAZE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Maze Therapeutics

NasdaqGM•Healthcare•Biotechnology

$26.21+0.34(0.01%)Market closed

Market Cap

$1.38B

P/S

69.1x

P/B

3.1x

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

How this company scores

WeakMetricSide Score: 37/100

Grade capped at D — Interest coverage below 1× (-39.1x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability6/25

Growth10/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Low leverageConsistent growthNet cash position

Grade capped at D

Interest coverage below 1× (-39.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 69.1x5y range 69.1x – 78.2x

P/B · 3.1x5y range 1.1x – 4.8x

Currently near its 6-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 6 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.38B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $20.00M
Q. Revenue: $0
TTM EBITDA: $-142.49M
TTM Op. Income: $-145.61M
Q. Op. Income: $-48.03M
TTM Net Income: $-133.59M
Q. Net Income: $-44.73M
EPS: $-0.76
Shares Out.: $59.00M

$20.00M in TTM revenue grew from zero YoY, reaching $0 last quarter. TTM EBITDA of $-142.49M and TTM operating income of $-145.61M show growth is flowing through to the bottom line. However, net income is negative at $133.59M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4803500000.0%
Net Margin: -4472700000.0%

Op. margin of -4803500000.0% is down 1156100000.0% YoY — costs are rising relative to revenue. Net margin at -4472700000.0% Over the past year, operating margin is down 32% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 69.1x
P/B Ratio: 3.1x

P/S of 69.1x and P/B of 3.1x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $531.63M
Cash: $202.64M
Long-Term Debt: $38.96M
Book Value: $453.12M
D/E Ratio: 0.1
Debt/EBITDA: N/A

With $531.63M in assets and $38.96M in long-term debt, D/E is 0.1and book value is $453.12M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 0% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-15.05M
TTM Free Cash Flow: $-106.84M
FCF Margin: -534.2%
FCF / Net Income: 0.8

TTM FCF of $-106.84M on $-15.05M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — an improving trend.